文献速递肾移植

肾移植后输注第三方间充质干细胞的I-II期开放标签临床研究

Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study.
PubMed 文献 · Kidney Int · 2018-12-06

该研究为开放标签I-II期试验,10例 deceased donor 肾移植受者移植后第3±2天单次输注第三方骨髓MSC(约2×10^6/kg),并与10例同期对照比较。MSC输注未观察不良事件,1例有心脏病史者输注后约3小时发生非ST段抬高型心肌梗死;机会性感染和急性排斥发生率相似。移植后第7天MSC组eGFR达48.6 ml/min/1.73m2,对照组32.5 ml/min/1.73m2;1年时eGFR无差异。MSC组第30天调节性T细胞频率增加,4例产生抗MSC或共享肾-MSC HLA抗体,仅1例MFI>1500。

要点

  • 肾移植后单次输注第三方骨髓MSC(约2×10^6/kg)总体安全,但1例输注后约3小时发生非ST段抬高型心肌梗死。
  • MSC组移植后第7天eGFR为48.6 ml/min/1.73m2,高于同期对照的32.5 ml/min/1.73m2,但1年时无差异。
  • MSC组第30天调节性T细胞频率增加,4例产生抗MSC或共享肾-MSC HLA抗体,仅1例MFI>1500。

核心结论

  • 肾移植后单次输注第三方MSC似乎安全,并与早期移植物功能改善和调节性T细胞比例增加相关。
  • 长期效应包括针对MSC的潜在免疫接种仍需研究。

研究设计与样本

  • 开放标签I-II期临床试验,10例 deceased donor 肾移植受者接受第三方骨髓MSC(约2×10^6/kg)单次输注,并与10例同期对照比较。
  • MSC于移植后第3±2天输注,所有受者均接受标准免疫抑制。

主要发现

  • MSC注射时未观察到不良事件;1例有心脏病史者输注后约3小时发生非ST段抬高型心肌梗死。
  • 机会性感染和急性排斥发生率相似。
  • 移植后第7天MSC组eGFR为48.6 ml/min/1.73m2,同期对照为32.5 ml/min/1.73m2,总体队列为29.3 ml/min/1.73m2;1年时eGFR无差异。
  • MSC组第30天调节性T细胞频率增加,B细胞频率无显著变化。
  • 4例MSC受者产生抗MSC或共享肾-MSC HLA抗体,仅1例MFI>1500。

关键数值与推荐

  • MSC剂量约为2×10^6/kg,移植后第3±2天单次输注。
  • 移植后第7天eGFR:MSC组48.6 ml/min/1.73m2,同期对照32.5 ml/min/1.73m2,总体队列29.3 ml/min/1.73m2。
  • 抗体检测:4例产生抗MSC或共享肾-MSC HLA抗体,仅1例MFI>1500。

临床怎么用

  • 肾移植后单次输注第三方MSC可能作为辅助免疫调节策略改善早期移植物功能。
  • 需监测输注相关不良事件,尤其是有心脏病史的受者。
  • 长期免疫原性和临床获益仍需进一步研究验证。

局限性

  • 开放标签设计,样本量小(MSC组10例,对照10例)。
  • 单次输注,随访1年,长期效应未评估。
  • 1例心脏事件与干预的关系不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mesenchymal stromal cells (MSCs) exhibit anti-inflammatory and immune-regulatory properties, and preclinical studies suggest a potential benefit in solid organ transplantation. We report on the 1-year follow-up of an open-label phase I-II trial of a single infusion of third-party MSC post-kidney transplantation, in addition to standard immunosuppression. Ten kidney transplant recipients from deceased donors received third-party bone marrow MSCs (∼2 × 106/kg) on day 3 ± 2 post-transplant and were compared to 10 concurrent controls. No adverse effects were noted at MSC injection. One participant with a history of cardiac disease had a non-ST-elevation myocardial infarction approximately 3 hours after MSC infusion. Incidences of opportunistic infections and acute rejection were similar. At day 7 post-transplant, estimated glomerular filtration rate (eGFR) in MSC-treated recipients reached 48.6 ml/min/1.73m2, compared to 32.5 ml/min/1.73m2 in controls and 29.3 ml/min/1.73m2 in our overall cohort of kidney transplant recipients. No difference in eGFR was found at 1 year. MSC-treated recipients showed increased frequencies of regulatory T cells at day 30, with no significant change in B cell frequencies compared to concurrent controls. Four MSC-treated participants developed antibodies against MSC or shared kidney-MSC HLA, with only 1 with MFI >1500. A single infusion of third-party MSC following kidney transplantation appears to be safe, with one cardiac event of unclear relationship to the intervention. MSC therapy is associated with increased regulatory T cell proportion and with improved early allograft function. Long-term effects, including potential immunization against MSC, remain to be studied.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Erpicum P, Weekers L, Detry O, et al. Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study. Kidney Int. 2018. PMID: 30528263. doi:10.1016/j.kint.2018.08.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。